Crescent Biopharma Gets FDA Clearance to Begin CR — 002 Trial

Crescent Biopharma received FDA clearance in October 2026 to begin clinical testing of CR-002, a PD-L1-targeting antibody-drug conjugate. The global Phase 1/2 APOLLO trial is scheduled to begin in fourth-quarter 2026, with initial data expected in second-half 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-066006), on October 15, 2026, and is solely responsible for the information contained therein. (C)